2024
Nutraceuticals Unveiled a Multifaceted Neuroprotective Mechanisms for Parkinson’s Disease: Elixir for the Brain
Soni D, Jamwal S, Chawla R, Singh S, Singh D, Singh T, Khurana N, Kanwal A, Dureja H, Patil U, Singh R, Kumar P. Nutraceuticals Unveiled a Multifaceted Neuroprotective Mechanisms for Parkinson’s Disease: Elixir for the Brain. Food Reviews International 2024, 40: 3079-3102. DOI: 10.1080/87559129.2024.2337766.Peer-Reviewed Original ResearchPre-clinicalGut-brain axisProtein ubiquitinationParkinson's diseaseMitochondrial dysfunctionSignaling pathwayMolecular mechanismsRelieve PD symptomsSymptoms of PDClinical trialsHealth benefits of nutraceuticalsBenefits of nutraceuticalsCustomized therapyClinical aspectsExpression of PDMediterranean dietNeurotransmitter imbalanceNeuroprotective mechanismsNeuroprotective potentialOxidative stressDiseasePD symptomsHealth benefitsSymptomsUbiquitin
2023
Age-associated sex difference in the expression of mitochondria-based redox sensitive proteins and effect of pioglitazone in nonhuman primate brain
Jamwal S, Blackburn J, Elsworth J. Age-associated sex difference in the expression of mitochondria-based redox sensitive proteins and effect of pioglitazone in nonhuman primate brain. Biology Of Sex Differences 2023, 14: 65. PMID: 37770961, PMCID: PMC10540392, DOI: 10.1186/s13293-023-00551-6.Peer-Reviewed Original ResearchConceptsSubstantia nigraSex-dependent expressionPrimate brainAdult male monkeysCerebrospinal fluidMale monkeysPeroxisome proliferator-activated receptor gamma agonistProliferator-activated receptor gamma agonistsEffect of pioglitazoneWeeks of treatmentReceptor gamma agonistsGreater expressionAdult female monkeysNonhuman primate brainNovel neuroprotective treatmentAfrican green monkeysSex-based differencesOral pioglitazoneNeuroprotective treatmentPIO treatmentRisk factorsCNS disordersGamma agonistsPreclinical studiesParkinson's disease
2021
Expression of PON2 isoforms varies among brain regions in male and female African green monkeys
Jamwal S, Blackburn JK, Elsworth JD. Expression of PON2 isoforms varies among brain regions in male and female African green monkeys. Free Radical Biology And Medicine 2021, 178: 215-218. PMID: 34890766, PMCID: PMC8760629, DOI: 10.1016/j.freeradbiomed.2021.12.005.Peer-Reviewed Original ResearchConceptsAfrican green monkeysParkinson's diseaseBrain regionsParaoxonase 2Different brain regionsFemale monkeysGreen monkeysPON2 expressionOxidative stress-related neurodegenerative disordersFemale African green monkeysNeurodegenerative disordersMale African green monkeysOxidative stressPON2 protein expressionAnti-inflammatory propertiesExpression levelsSignificant differencesBrain tissue samplesDorsolateral prefrontal cortexNeuroprotective strategiesWestern blotting techniquesDopaminergic neuronsPON2 proteinPrimate brainProtective rolePioglitazone transiently stimulates paraoxonase-2 expression in male nonhuman primate brain: Implications for sex-specific therapeutics in neurodegenerative disorders
Blackburn JK, Jamwal S, Wang W, Elsworth JD. Pioglitazone transiently stimulates paraoxonase-2 expression in male nonhuman primate brain: Implications for sex-specific therapeutics in neurodegenerative disorders. Neurochemistry International 2021, 152: 105222. PMID: 34767873, PMCID: PMC8712400, DOI: 10.1016/j.neuint.2021.105222.Peer-Reviewed Original ResearchConceptsPON2 expressionParkinson's diseaseParaoxonase 2Male African green monkeysShort-term animal modelsOxidative stressPeroxisome proliferator-activated receptor gammaEffect of pioglitazoneWeeks of treatmentProliferator-activated receptor gammaNonhuman primate brainParaoxonase-2 expressionRegion-dependent expressionSex-specific therapeuticsAnti-diabetic drug pioglitazoneAfrican green monkeysDorsolateral prefrontal cortexOral pioglitazonePreclinical evidenceSubstantia nigraClinical trialsPON2 mRNAAnimal modelsPioglitazonePrimate brainSex-based disparity in paraoxonase-2 expression in the brains of African green monkeys
Jamwal S, Blackburn JK, Elsworth JD. Sex-based disparity in paraoxonase-2 expression in the brains of African green monkeys. Free Radical Biology And Medicine 2021, 167: 201-204. PMID: 33722626, PMCID: PMC8096713, DOI: 10.1016/j.freeradbiomed.2021.03.003.Peer-Reviewed Original ResearchConceptsAfrican green monkeysParaoxonase 2Parkinson's diseaseBrain regionsGreen monkeysOxidative stressReactive oxygen speciesAnti-inflammatory propertiesSex-based disparitiesParaoxonase-2 expressionDifferent brain regionsNigrostriatal systemPON2 expressionDevelopment of therapeuticsNeurodegenerative disordersDiseaseProtein levelsROS levelsLower ROS levelsMitochondrial performanceSex-based variationDisordersMonkeysOxygen speciesMales
2020
Exploring the molecular approach of COX and LOX in Alzheimer’s and Parkinson’s disorder
Kumar A, Behl T, Jamwal S, Kaur I, Sood A, Kumar P. Exploring the molecular approach of COX and LOX in Alzheimer’s and Parkinson’s disorder. Molecular Biology Reports 2020, 47: 9895-9912. PMID: 33263931, DOI: 10.1007/s11033-020-06033-x.Peer-Reviewed Original ResearchConceptsParkinson's diseaseDocosahexaenoic acidAlzheimer's diseaseArachidonic acidLipid mediatorsAnti-inflammatory actionAppropriate therapeutic optionPro-inflammatory eicosanoidsProduction of eicosanoidsResolution of inflammationRole of AACOX-2 enzymeLOX pathwayNeuroinflammatory responseNeuroinflammatory eventsTherapeutic optionsAD patientsCytokine secretionEpidemiological studiesLeukocyte traffickingNF-κBEicosanoid productionBrain disordersNeurological disordersCyclooxygenasePPARγ/PGC1α signaling as a potential therapeutic target for mitochondrial biogenesis in neurodegenerative disorders
Jamwal S, Blackburn J, Elsworth JD. PPARγ/PGC1α signaling as a potential therapeutic target for mitochondrial biogenesis in neurodegenerative disorders. Pharmacology & Therapeutics 2020, 219: 107705. PMID: 33039420, PMCID: PMC7887032, DOI: 10.1016/j.pharmthera.2020.107705.Peer-Reviewed Original ResearchConceptsNeurodegenerative disordersParkinson's diseaseAlzheimer's diseaseParaoxonase 2Mitochondrial biogenesisNeurodegenerative diseasesHuntington's diseasePeroxisome proliferator-activated receptorProliferator-activated receptorPotential therapeutic targetDevastating neurological disorderFunction of neuronsPeroxisome proliferator-activated receptor gamma co-activator-1 alphaPharmacological-based therapiesSymptomatic treatmentCurrent therapiesClinical trialsLigand-inducible transcription factorsTherapeutic targetNeurological disordersDiseasePPARγ modulatorsProgressive lossMitochondrial dysfunctionPromising target
2019
Insight Into the Emerging Role of Striatal Neurotransmitters in the Pathophysiology of Parkinson’s Disease and Huntington’s Disease: A Review
Jamwal S, Kumar P. Insight Into the Emerging Role of Striatal Neurotransmitters in the Pathophysiology of Parkinson’s Disease and Huntington’s Disease: A Review. Current Neuropharmacology 2019, 17: 165-175. PMID: 29512464, PMCID: PMC6343208, DOI: 10.2174/1570159x16666180302115032.Peer-Reviewed Original ResearchConceptsParkinson's diseaseHuntington's diseaseStriatal neurotransmittersNeuronal deathNeurotransmitter levelsAltered neurotransmitters levelBasal ganglia regionsExcitotoxic neuronal deathNeurotransmitter alterationsBrain dopaminePathophysiological basisBasal gangliaGanglia regionsMovement disordersPreclinical studiesReceptor densitySpecific drugsCoordinated body movementsDiseaseNeurotransmittersAltered levelsOxidative stressExact mechanismMitochondrial dysfunctionImportant neurotransmitter
2017
Animal Models of Parkinson’s Disease
Sharma N, Jamwal S, Singh S, Gill H, Bansal P. Animal Models of Parkinson’s Disease. 2017, 23-42. DOI: 10.1007/978-981-10-5981-0_3.Peer-Reviewed Original ResearchParkinson's diseaseDopaminergic neuronsLewy bodiesPrevalence of PDCranial nerve motor nucleiHypokinetic movement disordersNigrostriatal dopaminergic neuronsNon-motor symptomsMajor pathological featureAge related neurodegenerative diseasesRelated neurodegenerative diseasesInheritable genetic mutationsProgressive neurodegenerativeAutonomic dysfunctionOrthostatic hypotensionIdiopathic originNeuropsychiatric disturbancesCerebral cortexMotor manifestationsMotor nucleusNucleus basalisPathological featuresSleep disturbancesLocus coeruleusSelective degeneration
2016
Beneficial effect of antidepressants against rotenone induced Parkinsonism like symptoms in rats
Sharma N, Jamwal S, Kumar P. Beneficial effect of antidepressants against rotenone induced Parkinsonism like symptoms in rats. Pathophysiology 2016, 23: 123-134. PMID: 26996500, DOI: 10.1016/j.pathophys.2016.03.002.Peer-Reviewed Original ResearchRotenone administrationCommon age-related neurodegenerative disorderDay one hourPro-inflammatory mediatorsAge-related neurodegenerative disordersLevels of catecholaminesTreatment of PDPathogenesis of PDLevodopa combinationAdjuvant therapyDA neuronsNeuroprotective roleCatecholamine levelsDifferent antidepressantsNeurotransmitter dysfunctionCNS disordersParkinson's diseaseMotor coordinationBody weightAntidepressantsSNpc regionNeurodegenerative disordersParkinsonismBeneficial effectsSertraline